Definitive Healthcare’s (DH) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Definitive Healthcare (NASDAQ:DH) in a research note issued to investors on Wednesday morning, Benzinga reports.

A number of other analysts have also recently weighed in on DH. Canaccord Genuity Group increased their target price on shares of Definitive Healthcare from $9.00 to $10.00 and gave the stock a hold rating in a report on Thursday, February 29th. Barclays increased their price objective on shares of Definitive Healthcare from $10.00 to $11.00 and gave the stock an equal weight rating in a research note on Friday, March 1st. Morgan Stanley downgraded Definitive Healthcare from an overweight rating to an equal weight rating and decreased their target price for the company from $11.50 to $9.00 in a research note on Wednesday. Finally, Stifel Nicolaus lowered their target price on Definitive Healthcare from $12.00 to $11.00 and set a buy rating for the company in a report on Wednesday, January 17th. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of Hold and a consensus price target of $10.81.

Definitive Healthcare Stock Down 2.8 %

NASDAQ:DH opened at $5.20 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.31 and a current ratio of 2.31. The company has a market capitalization of $612.51 million, a price-to-earnings ratio of -3.01, a price-to-earnings-growth ratio of 6.12 and a beta of 1.41. Definitive Healthcare has a one year low of $4.38 and a one year high of $12.45. The stock has a 50-day simple moving average of $7.70 and a 200 day simple moving average of $8.29.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.02). The firm had revenue of $65.93 million during the quarter, compared to analyst estimates of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. Sell-side analysts predict that Definitive Healthcare will post 0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its holdings in Definitive Healthcare by 599.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after purchasing an additional 4,959 shares during the period. Norden Group LLC bought a new stake in shares of Definitive Healthcare during the 1st quarter worth about $83,000. Berry Wealth Group LP acquired a new stake in shares of Definitive Healthcare in the 1st quarter worth approximately $99,000. SG Americas Securities LLC bought a new position in shares of Definitive Healthcare in the third quarter valued at approximately $116,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Definitive Healthcare in the first quarter valued at approximately $120,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.